Granulocyte colony-stimulating factor
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Granulocyte Colony-Stimulating Factor (G-CSF or GCSF) is a colony-stimulating factor hormone. It is a glycoprotein, growth factor or cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to pulse them out of the marrow into the blood. It also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
G-CSF is also known as Colony-Stimulating Factor 3 (CSF 3).
Biological function
G-CSF is produced by endothelium, macrophages, and a number of other immune cells. The natural human glycoprotein exists in two forms, a 174- and 180-amino-acid-long protein of molecular weight 19,600 grams per mole. The more-abundant and more-active 174-amino acid form has been used in the development of pharmaceutical products by recombinant DNA (rDNA) technology.
Mouse granulocyte colony-stimulating factor (G-CSF) was first recognised and purified in Australia in 1983, and the human form was cloned by groups from Japan and the United States in 1986.
The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates proliferation and differentiation into mature granulocytes.
Genetics
The gene for G-CSF is located on chromosome 17, locus q11.2-q12. Nagata et al. found that the GCSF gene has 4 introns, and that 2 different polypeptides are synthesized from the same gene by differential splicing of mRNA.[1]
The 2 polypeptides differ by the presence or absence of 3 amino acids. Expression studies indicate that both have authentic GCSF activity.
It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element.
Therapeutic use
G-CSF stimulates the production of white blood cells (WBC). In oncology and hematology, a recombinant form of G-CSF is used with certain cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens. Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections and sepsis. However, in a Washington University School of Medicine study using mice, G-CSF is shown to lessen the density of bone tissue even while it increases the WBC count;[citation needed] if this is found to occur in human cases it would necessitate increased consumption of calcium and vitamins A and D, and maybe drug therapy.
G-CSF is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation. It may also be given to the receiver, to compensate for conditioning regimens.
Itescu planned in 2004 to use G-CSF to treat heart degeneration by injecting it into the blood-stream, plus SDF (stromal cell-derived factor) directly to the heart.[1]
The recombinant human G-CSF synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta) are two commercially-available forms of rhG-CSF (recombinant human G-CSF). The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections.
Another form of recombinant human G-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies.
See also
References
Further reading
- Duarte RF, Franf DA (2003). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance.". Leuk. Lymphoma 43 (6): 1179-87. PMID 12152985.
- Mroczko B, Szmitkowski M (2005). "Hematopoietic cytokines as tumor markers.". Clin. Chem. Lab. Med. 42 (12): 1347-54. doi:10.1515/CCLM.2004.253. PMID 15576295.
- Sallerfors B, Olofsson T (1993). "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays.". Eur. J. Haematol. 49 (4): 199-207. PMID 1281454.
- Zink T, Ross A, Ambrosius D, et al. (1993). "Secondary structure of human granulocyte colony-stimulating factor derived from NMR spectroscopy.". FEBS Lett. 314 (3): 435-9. PMID 1281794.
- Kubota N, Orita T, Hattori K, et al. (1990). "Structural characterization of natural and recombinant human granulocyte colony-stimulating factors.". J. Biochem. 107 (3): 486-92. PMID 1692828.
- Souza LM, Boone TC, Gabrilove J, et al. (1986). "Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.". Science 232 (4746): 61-5. doi:10.1126/science.2420009. PMID 2420009.
- Nagata S, Tsuchiya M, Asano S, et al. (1986). "The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor.". EMBO J. 5 (3): 575-81. PMID 2423327.
- Simmers RN, Smith J, Shannon MF, et al. (1988). "Localization of the human G-CSF gene to the region of a breakpoint in the translocation typical of acute promyelocytic leukemia.". Hum. Genet. 78 (2): 134-6. doi:10.1007/BF00278182. PMID 2448221.
- Tweardy DJ, Cannizzaro LA, Palumbo AP, et al. (1988). "Molecular cloning and characterization of a cDNA for human granulocyte colony-stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21.". Oncogene Res. 1 (3): 209-20. PMID 2453015.
- Tsuchiya M, Nomura H, Asano S, et al. (1987). "Characterization of recombinant human granulocyte-colony-stimulating factor produced in mouse cells.". EMBO J. 6 (3): 611-6. PMID 3034599.
- Nagata S, Tsuchiya M, Asano S, et al. (1986). "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.". Nature 319 (6052): 415-8. doi:10.1038/319415a0. PMID 3484805.
- Devlin JJ, Devlin PE, Myambo K, et al. (1987). "Expression of granulocyte colony-stimulating factor by human cell lines.". J. Leukoc. Biol. 41 (4): 302-6. PMID 3494801.
- Kanda N, Fukushige S, Murotsu T, et al. (1987). "Human gene coding for granulocyte-colony stimulating factor is assigned to the q21-q22 region of chromosome 17.". Somat. Cell Mol. Genet. 13 (6): 679-84. doi:10.1007/BF01534488. PMID 3499671.
- Le Beau MM, Lemons RS, Carrino JJ, et al. (1988). "Chromosomal localization of the human G-CSF gene to 17q11 proximal to the breakpoint of the t(15;17) in acute promyelocytic leukemia.". Leukemia 1 (12): 795-9. PMID 3501046.
- Zink T, Ross A, Lüers K, et al. (1994). "Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein.". Biochemistry 33 (28): 8453-63. doi:10.1021/bi00194a009. PMID 7518249.
- Corcione A, Baldi L, Zupo S, et al. (1994). "Spontaneous production of granulocyte colony-stimulating factor in vitro by human B-lineage lymphocytes is a distinctive marker of germinal center cells.". J. Immunol. 153 (7): 2868-77. PMID 7522243.
- Watari K, Ozawa K, Tajika K, et al. (1994). "Production of human granulocyte colony stimulating factor by various kinds of stromal cells in vitro detected by enzyme immunoassay and in situ hybridization.". Stem Cells 12 (4): 416-23. PMID 7524894.
- Hill CP, Osslund TD, Eisenberg D (1993). "The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors.". Proc. Natl. Acad. Sci. U.S.A. 90 (11): 5167-71. doi:10.1073/pnas.90.11.5167. PMID 7685117.
- Haniu M, Horan T, Arakawa T, et al. (1996). "Extracellular domain of granulocyte-colony stimulating factor receptor. Interaction with its ligand and identification of a domain in close proximity of ligand-binding region.". Arch. Biochem. Biophys. 324 (2): 344-56. doi:10.1006/abbi.1995.0047. PMID 8554326.
- McCracken S, Layton JE, Shorter SC, et al. (1996). "Expression of granulocyte-colony stimulating factor and its receptor is regulated during the development of the human placenta.". J. Endocrinol. 149 (2): 249-58. doi:10.1677/joe.0.1490249. PMID 8708536.
External links
Cytokines, glycoproteins: colony-stimulating factors | |
|---|---|
| Numbered | Macrophage colony-stimulating factor - Granulocyte macrophage colony-stimulating factor - Granulocyte colony-stimulating factor |
| Unnumbered | Erythropoietin - Thrombopoietin - Interleukin 3 |
Immunomodulators - immunostimulants (L03) | |
|---|---|
| Colony stimulating factors | G-CSF (Filgrastim/Pegfilgrastim, Lenograstim) - GM-CSF (Molgramostim, Sargramostim) - SCF (Ancestim) |
| Interferons | alpha: Interferon alpha natural - Interferon alpha-2a/Peginterferon alpha-2a - Interferon alpha-2b/Peginterferon alpha-2b - Interferon alpha-n1 - Interferon alphacon-1
beta: Interferon beta natural - Interferon beta-1a - Interferon beta-1b Interferon gamma |
| Interleukins | Aldesleukin - Oprelvekin |
| Other cytokines and endogenous immunostimulants | Female sex steroids - Pegademase - Poly ICLC - Immunocyanin - Tasonermin - Histamine dihydrochloride - prolactin - growth hormone - vitamin D |
| Exogenous | Lentinan - Roquinimex - BCG vaccine - Pidotimod - Poly I:C - Thymopentin - Melanoma vaccine - Glatiramer acetate - |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

